NCODA Logo

NEWS

Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

September 12, 2022

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement August 26, 2022 – This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor […]
read more

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

September 12, 2022

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 – Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – – NDA Submission to the U.S. FDA […]
read more

MAINE CONTINUES REFORM FOR PATIENTS

September 6, 2022

FOR IMMEDIATE RELEASE September 6, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org In two consecutive legislative sessions in 2021 and 2022, the state of Maine has focused on reform for patients battling cancer. The legislative bodies in Maine […]
read more

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)

August 26, 2022

New Approval Alert  The U.S. Food and Drug Administration approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patient one year and older with cGvHD after failure of one or more lines of systemic therapy. Official statement HERE.  
read more

Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies

August 19, 2022

NCODA applauds the recent published article in the American Journal of Managed Care® by our members at Florida Cancer Specialists and Research Institute titled “Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies.” Click the link below to read this article: https://www.ajmc.com/view/defining-appropriate-quality-performance-metrics-for-pharmacies-dispensing-oral-oncology-therapies  
read more

NCODA and Florida Cancer Specialists & Research Institute Announce New Oncology Stakeholder Education Exchange Program

August 16, 2022

Cazenovia, NY, August 16, 2022 –  New cancer treatment therapies, technologies and innovations continue to be discovered and approved for use at a rapid pace, creating an education challenge for physicians and other healthcare professionals within the complex oncology landscape. Working collaboratively with Florida Cancer Specialists & Research Institute, LLC (FCS), NCODA, Inc. developed a […]
read more

Cazenovia nonprofit to host ‘Passion Fore Patients’ Golf Tournament

August 9, 2022

Cazenovia nonprofit to host ‘Passion Fore Patients’ Golf Tournament
read more

Financial Impact of Medically Integrated Pharmacy Interventions on Oral Oncolytic Prescriptions

August 2, 2022

The NCODA CAWT Tool was recently published in the Journal of Clinical Oncology – Oncology Practice. The article highlights the medication waste associated with external specialty pharmacies compared to Medically Integrated Pharmacies (MIPs), as well as increased cost avoidance demonstrated by MIP teams. As the utilization of oral cancer medications rises, it is vital that cancer centers track costs associated with […]
read more

NCODA Announces New Education Platform for the Medically-Integrated Oncology Community

July 27, 2022

NCODA University Offers Complimentary Accredited Learning Through Virtual and In-Person Events CAZENOVIA, NY, July 27, 2022 – Empowering all stakeholders in oncology with easily accessible, patient-centered education and collaborative learning opportunities is fundamental to NCODA, Inc. Today, NCODA, launches NCODA University, a new division of the organization, which will allow medically-integrated oncology professionals to obtain […]
read more

Florida Takes Action Against Prescription Drug Pricing

July 14, 2022

FOR IMMEDIATE RELEASE July 14, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org Florida Takes Action Against Prescription Drug Pricing   NCODA is proud to share that on July 8, 2022, Florida Governor Ron DeSantis issued Executive Order 22-164 […]
read more

Three Oncology Leaders Join NCODA Executive Council

July 7, 2022

FOR IMMEDIATE RELEASE July 7, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629 CAZENOVIA, NY – NCODA is pleased to announce the appointment of three oncology leaders to the Executive Council: Meg Butler, PharmD (Clearview Cancer Institute), Gury Doshi, MD (Texas Oncology), and Xylina Gregg, MD (Utah Cancer Specialists). “Our Executive Council is comprised of a […]
read more

NCODA International Abstract Published in Croatian Journal of Oncology

July 5, 2022

NCODA recently published an abstract titled “The NCODA PQI: Educating Your Medically Integrated Team While Supporting Better Patient Care with a Concise, Peer-Reviewed,Pharmacy-Led Resource” in the Croatian Journal of Oncology. This abstract is based on a presentation that our Founder & Executive Director, Michael Reff, RPh, MBA, delivered at the Croatian Virtual Congress of Oncology Pharmacy. Click HERE […]
read more

RESOURCES

Cost Avoidance Waste Tracker

Positive Quality Interventions

PQI in Action

OCE Sheets

IVE Sheets

Treatment Support Kits

PQI Podcast

Members

Member Resources

OPTA

Committees

Member Login

Events

Webinars

Spring Forum

Oncology Institute

PSO Annual Meeting

Fall Summit

contact@ncoda.org

315-655-4640

P.O. Box 468
Cazenovia, NY 13035

NCODA Logo

NCODA is a 501(c)(3) Organization